RGLS Form 4: Insider Equity Cashed Out at $7 + CVR in Novartis Merger
Rhea-AI Filing Summary
Regulus Therapeutics Inc. (ticker RGLS) filed a Form 4 reporting that Senior Vice President & General Counsel Christopher Ray Aker disposed of all remaining equity interests on 25 June 2025, the day the company completed its merger with an indirect Novartis AG subsidiary (Redwood Merger Sub Inc.).
Key cash-and-CVR consideration: Each common share, performance stock unit (PSU) and in-the-money stock option was converted into (i) $7.00 in cash and (ii) one contingent value right (CVR) that may deliver an additional $7.00 per share upon achievement of a specified milestone. Out-of-the-money options (exercise price ≥ $7.00 < $14.00) were canceled and exchanged solely for CVRs, giving holders potential—but not guaranteed—future cash.
Securities disposed:
- 60,796 common shares tendered for cash + CVR.
- 83,125 PSUs canceled for cash + CVR (previously omitted from filings).
- Total of 1,471,000 stock options across 11 tranches canceled; options with strike < $7 receive cash + CVR, those with strike ≥ $7 < $14 receive only CVRs.
As a result, Aker reports zero shares or options beneficially owned post-transaction. The filing confirms legal completion of the merger and outlines how insiders’ equity was settled, providing investors final clarity on consideration mechanics and eliminating further insider ownership disclosures under Section 16.
Positive
- Merger completion confirmed – Form 4 indicates the cash tender closed on 25 Jun 2025, eliminating deal-completion risk.
- Clear consideration mechanics – Investors now know insiders received $7.00 cash plus a CVR per share/option, aligning with public terms.
- Regulatory compliance – Insider corrected prior omission of 83,125 PSUs, demonstrating transparent reporting.
Negative
- None.
Insights
TL;DR – Form 4 confirms Novartis cash-and-CVR buyout closed; insider’s equity fully cashed out, no residual ownership.
The disclosure is a procedural but important post-closing step. It verifies that the $7.00 per share tender plus CVR structure outlined in the 29 Apr 2025 merger agreement was executed on 25 Jun 2025. All insider equity—including ~1.47 million options—was canceled, eliminating any remaining stand-alone RGLS float. While the economics were set earlier, the filing removes any uncertainty about treatment of PSUs and options and ensures CVRs are properly allocated. For arbitrage and event-driven investors, it is a final confirmation that the transaction has closed on schedule, converting equity risk into CVR milestone risk.
TL;DR – Filing is neutral-to-positive: fulfills Section 16 duties, shows clean exit, no governance red flags.
Aker’s Form 4 demonstrates compliance with insider reporting obligations after the merger. The correction for previously omitted 83,125 PSUs is transparently disclosed, reducing potential regulatory exposure. The zero post-close holdings underscore full integration into Novartis and suspension of further insider reporting. Governance risk is low as consideration terms mirror the proxy-disclosed merger agreement.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option | 2,500 | $0.00 | -- |
| Disposition | Stock Option | 750 | $0.00 | -- |
| Disposition | Stock Option | 33,500 | $0.00 | -- |
| Disposition | Stock Option | 21,000 | $0.00 | -- |
| Disposition | Stock Option | 48,000 | $0.00 | -- |
| Disposition | Stock Option | 7,000 | $0.00 | -- |
| Disposition | Stock Option | 45,000 | $0.00 | -- |
| Disposition | Stock Option | 393,750 | $0.00 | -- |
| Disposition | Stock Option | 70,000 | $0.00 | -- |
| Disposition | Stock Option | 363,000 | $0.00 | -- |
| Disposition | Stock Option | 487,500 | $0.00 | -- |
| U | Common Stock | 60,796 | $0.00 | -- |
| Disposition | Common Stock | 83,125 | $0.00 | -- |
Footnotes (1)
- This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the "Merger Agreement"), by and among Regulus Therapeutics Inc. (the "Issuer"), Redwood Merger Sub Inc. ("Merger Sub"), a wholly owned, indirect subsidiary of Novartis AG ("Parent"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the "Shares"), in exchange for (a) $7.00 in cash per Share (the "Closing Amount"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a "CVR") per Share. Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the "Offer Price"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for the Offer Price. Pursuant to the terms of the Merger Agreement, each performance stock unit ("PSU") was canceled and converted into the right to receive (A) an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of Shares underlying such PSU immediately prior to the Effective Time by (y) the Closing Amount plus (B) one CVR with respect to each such Share subject to such PSU immediately prior to the Effective Time. The 83,125 PSUs reported herein were unintentionally omitted from previous Form 4 filings made by the Reporting Person following the achievement of the performance-based vesting conditions applicable thereto. Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an "In-the-Money Option") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time. Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an "Out-of-the-Money Option") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option).
